Assessment of tandem mass spectrometry and high-resolution mass spectrometry for the analysis of bupivacaine in plasma.

about

Identification of Novel Opioid Interferences using High-Resolution Mass Spectrometry.

P2860

Q44349501-D391795D-0D12-4142-B197-A70979429153

P2860

Assessment of tandem mass spectrometry and high-resolution mass spectrometry for the analysis of bupivacaine in plasma.

Item

http://www.wikidata.org/entity/Q35627328

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Assessment of tandem mass spec ...... ysis of bupivacaine in plasma.

@ast

Assessment of tandem mass spec ...... ysis of bupivacaine in plasma.

@en

type

Item

label

Assessment of tandem mass spec ...... ysis of bupivacaine in plasma.

@ast

Assessment of tandem mass spec ...... ysis of bupivacaine in plasma.

@en

prefLabel

Assessment of tandem mass spec ...... ysis of bupivacaine in plasma.

@ast

Assessment of tandem mass spec ...... ysis of bupivacaine in plasma.

@en

P1476

Assessment of tandem mass spec ...... ysis of bupivacaine in plasma.

@en

P2093

Fleur Gaudette

http://www.w3.org/2001/XMLSchema#string

Francis Beaudry

http://www.w3.org/2001/XMLSchema#string

Javier Benito

http://www.w3.org/2001/XMLSchema#string

Paulo Steagall

http://www.w3.org/2001/XMLSchema#string

P2860

LC/MS applications in drug development

Data acquisition and data mining techniques for metabolite identification using LC coupled to high-resolution MS.

Retrospective data analysis and proposal of a practical acceptance criterion for inter-laboratory cross-validation of bioanalytical methods using liquid chromatography/tandem mass spectrometry.

Liquid chromatography/atmospheric pressure ionization-mass spectrometry in drug metabolism studies.

Critical topics in ensuring data quality in bioanalytical LC-MS method development.

Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery.

Making better drugs: Decision gates in non-clinical drug development.

First metabolic profile of XLR-11, a novel synthetic cannabinoid, obtained by using human hepatocytes and high-resolution mass spectrometry

Mass spectrometry for the quantification of bioactive peptides in biological fluids.

Targeted proteomics for validation of biomarkers in clinical samples

P304

1724-1730

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/BMC.3485

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-05-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25963121

http://www.w3.org/2001/XMLSchema#string

Assessment of tandem mass spectrometry and high-resolution mass spectrometry for the analysis of bupivacaine in plasma.

about

P2860

P2860

Assessment of tandem mass spectrometry and high-resolution mass spectrometry for the analysis of bupivacaine in plasma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698